31 Jul
Posted by bulletin as All Topics
The introduction of Shantha’s vaccine to fight the dreaded liver disease forced SmithKline Beecham to slash prices of its vaccine brand Engerix-B, after enjoying a monopoly market in India.
RSS feed for comments on this post · TrackBack URI
Name (required)
E-mail (required, never displayed)
URI
Bulletin India is proudly powered by WordPress - BloggingPro theme by: Design Disease
RSS feed for comments on this post · TrackBack URI
Leave a reply